Introduction {#sec1}
============

Atelectasis from endobronchial obstruction or external bronchial compression may cause respiratory distress and obstructive pneumonia.[@bib1], [@bib2] Rapid initiation of treatment is important to open the obstruction and relieve symptoms. Endobronchial lesions respond well to treatment with invasive bronchoscopic techniques such as laser ablation, cryotherapy, and stent placement and, if treated early, patients will often experience rapid lung reexpansion.[@bib3], [@bib4]

When atelectasis is from external bronchial compression or if invasive bronchoscopic techniques are unavailable, obstructing tumors are often treated with radiation therapy (RT). Accurate placement of radiation fields is challenging because of difficulty in differentiating between tumor and atelectatic lung on computed tomography (CT) images alone.[@bib5] In addition, lung reexpansion during the course of treatment may shift the location of the tumor and normal structures away from their original positions. Replanning of the radiation fields to account for changing organ position resulting from lung reexpansion is essential to ensure treatment accuracy. We hypothesized that facilitating lung reexpansion before initiation of RT would improve treatment accuracy and reduce the need for replanning radiation treatments.

We report the occurrence of reexpansion of right upper lobe (RUL) atelectasis in a patient with small cell lung cancer caused by use of continuous positive airway pressure (CPAP) during RT treatment planning.

Case presentation {#sec2}
=================

A 52-year-old woman with a 60 pack-year history of smoking and a history of ischemic heart disease presented complaining of sweating, coughing, and shortness of breath. Chest x- ray and CT scans showed an RUL mass, atelectasis, mediastinal widening, and a right-sided pleural effusion. Positron emission tomography (PET)-CT scan ([Fig 1](#fig1){ref-type="fig"}A,B) showed disease limited to the thorax. Contrast enhanced CT of the brain was normal. Bronchoscopy showed extrinsic compression and infiltration of the RUL and the right middle lobe bronchi. Bronchoscopic biopsy showed small cell lung cancer. Thoracentesis showed no malignant cells in pleural fluid. Systemic treatment was initiated with cis-platinum and etoposide. She developed acute renal failure after 2 cycles. After recovery, 2 cycles of carbo-platinum and etoposide were given.Figure 1(A, B) Diagnostic positron emission tomography computed tomography scan before initiation of chemotherapy.

The patient was referred for outpatient RT. She complained of persistent cough and dyspnea on exertion. She continued to smoke. Physical examination showed a thin woman in no respiratory distress. Vital signs were normal. Breath sounds were absent in the right upper and mid-chest. The liver and spleen were not palpable. The extremities were without edema. The prescribed dose was 60 Gy specified as 95% dose to 95% of the planning target volume. The initial planning CT ([Fig 2](#fig2){ref-type="fig"}A) showed partial reduction in the RUL mass and persistent RUL atelectasis. The total lung volume was 2170 mL. Mean lung dose (MLD), V5, and V20 were 20.5 Gy, 51.8%, and 34.8%, respectively. The patient was offered participation on an Institutional Ethics Committee--approved trial to evaluate CPAP for improving RT delivery by reducing respiratory motion. Resolution of atelectasis was not an indication for participation. After obtaining informed consent, CPAP training began within the RT department before CT simulation by administering CPAP for 1 hour at 15 cm H~2~O.[@bib6] After 30 minutes, she complained of vertigo, headache, and weakness and refused further training or CT simulation. The next day, she reported less dyspnea. She returned in 1 week and completed CPAP training and CT simulation without difficulty. CT simulation with CPAP ([Fig 2](#fig2){ref-type="fig"}B) showed reexpansion of the RUL. [Table 1](#tbl1){ref-type="table"} shows that with use of CPAP total lung volume increased 74% to 3,767 mL, GTV, CTV and planning target volume decreased 46%, 45%, and 38%, respectively. [Figure 3](#fig3){ref-type="fig"} shows a dose-volume histogram comparing dose with tumor and normal structures with and without CPAP. MLD and mean heart dose decreased 20% and 51%, respectively.Figure 2(A) Planning computed tomography (CT) scan without continuous positive airway pressure (CPAP). (B) Planning CT scan with CPAP.Figure 3Dose volume histogram showing doses with and without continuous positive airway pressure.Table 1Size of planning structures and dose to normal organs with and without CPAPParametersFBCPAPΔ%GTV (mL)388209−179−46CTV (mL)605331−275−45PTV (mL)902560−342−38Lung volume (mL)217037671597+74Mean lung dose (Gy)20.516.3−4−20V5 (%)51.843.9−8−15V20 (%)34.827.4−7−21Heart volume (mL)5105155+1Mean heart dose (Gy)16.48.0−8−51V10 (%)37.721.0−17−44V20 (%)28.310.6−18−62V30 (%)21.57.1−14−67Mean spine dose (Gy)18.512.7−6−31Mean esophagus dose (Gy)37.731.1−7−17

CPAP was used daily with the same technique as used during simulation: for 1 hour before and during treatment. [Figure 4](#fig4){ref-type="fig"} shows a cone beam CT image from day 11 demonstrating that the RUL remained inflated throughout treatment.Figure 4Cone beam computed tomography scan showing persistent lung expansion during course of treatment.

After the 11th treatment, the patient began complaining of headaches, weakness, and confusion. A magnetic resonance imaging scan of the brain suggested leptomeningeal disease. Chest RT was discontinued, and RT to the cranial contents were started. She died 8 weeks posttreatment.

Discussion {#sec3}
==========

To the best of our knowledge, this is the first reported case describing use of CPAP for reexpansion of obstructive atelectasis from malignancy before RT. CPAP has been long used as a treatment for sleep apnea and more recently as a prophylactic therapy and treatment for postoperative atelectasis.[@bib7] In this case, the intent of CPAP was to reduce respiratory motion and preserve normal lung function. Reexpansion of the RUL atelectasis was an unexpected benefit that persisted throughout the course of RT.

When atelectasis is present, functional imaging studies such as PET-CT provide improved discrimination between collapsed lung and tumor and are useful for planning RT.[@bib8] However, use of PET-CT in treatment planning is often limited because studies obtained before developing atelectasis may not provide an accurate representation of the tumor location once atelectasis occurs. Scans obtained when atelectasis is present may lose usefulness as the atelectatic lung reexpands. Furthermore, there may be insufficient time to obtain PET-CT imaging before initiating RT in patients who present with rapid onset of symptoms.[@bib5]

Recently, our group reported reduced tumor motion and expanded lung volumes in patients who received stereotactic body RT with CPAP.[@bib6] The improvements observed in this case were largely consistent with our earlier findings, which showed an increase in total lung volume and decrease in dose to the lung and heart.[@bib6] Although CPAP had no effect on GTV in our earlier study, in this case report, GTV was reduced by 46% because of reexpansion of the lung and improved identification of tumor for contouring.[@bib6] The decreases in lung V5, V20, and MLD with CPAP were less than expected because some of the reexpanded lung was irradiated. The decrease in heart dose was substantial because depression of the diaphragm repositioned the heart out of the path of the radiation beam.

Reexpansion of atelectasis with chemotherapy alone is uncommon and lung reexpansion often occurs only after RT is added to the therapeutic plan.[@bib9] In this case, the reduction in tumor volume from the first 4 cycles of chemotherapy contributed to the rapid lung reexpansion and resolution of atelectasis caused by the use of CPAP. Because this patient received no additional chemotherapy between simulations, the vertigo, headaches, and weakness the patient described during the first use of CPAP may have been caused by lung reexpansion. However, use of CPAP may also have caused a transient early occurrence of symptoms from the leptomeningeal disease that presented soon after starting RT. However, the absence of symptom recurrence during subsequent CPAP use suggests that these initial symptoms were due to lung reexpansion rather than leptomeningeal tumor.

Because a 4-dimensional scan was not obtained during the initial simulation, we were unable to fully assess the reduction in respiratory motion caused by use of CPAP. A 4-dimensional scan was obtained during the simulation with CPAP and showed negligible tumor motion and was not used for planning. Because our experience with CPAP is limited, we are unable to offer guidelines for selection of patients with atelectasis most likely to benefit from treatment with CPAP. Also, we do not know if longer duration or repeated use of CPAP may prove to be effective in patients who are refractory to initial use of CPAP treatment. The use of CPAP to facilitate reexpansion of atelectasis does not replace other available therapeutic options. Instead, CPAP is an additional therapeutic option to consider that may facilitate lung reexpansion before initiation of RT. Further study is suggested to better define appropriate patient selection and optimize the use of this technique.

Conclusion {#sec4}
==========

The use of CPAP caused reexpansion of atelectasis resulting from malignant bronchial obstruction. Lung reexpansion improved treatment planning by allowing for better identification and targeting of the obstructing lesion, sparing of normal lung tissue from radiation exposure, and reducing the need for replanning treatment. Further study to assess the use of CPAP for reexpansion of atelectasis resulting from malignant bronchial obstruction is indicated.
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